< Return to Video

How we're using AI to discover new antibiotics

  • 0:01 - 0:04
    So how are we going to beat
    this novel coronavirus?
  • 0:04 - 0:07
    By using our best tools:
  • 0:07 - 0:10
    our science and our technology.
  • 0:10 - 0:13
    In my lab, we're using
    the tools of artificial intelligence
  • 0:13 - 0:15
    and synthetic biology
  • 0:15 - 0:18
    to speed up the fight
    against this pandemic.
  • 0:18 - 0:21
    Our work was originally designed
  • 0:21 - 0:23
    to tackle the antibiotic
    resistance crisis.
  • 0:23 - 0:26
    Our project seeks to harness
    the power of machine learning
  • 0:26 - 0:30
    to replenish our antibiotic arsenal
  • 0:30 - 0:33
    and avoid a globally devastating
    post-antibiotic era.
  • 0:34 - 0:37
    Importantly, the same technology
    can be used to search
  • 0:37 - 0:39
    for antiviral compounds
  • 0:39 - 0:42
    that could help us fight
    the current pandemic.
  • 0:42 - 0:46
    Machine learning is turning
    the traditional model of drug discovery
  • 0:46 - 0:48
    on its head.
  • 0:48 - 0:49
    With this approach,
  • 0:49 - 0:51
    instead of painstakingly testing
    thousands of existing molecules
  • 0:51 - 0:53
    one by one in a lab
    for their effectiveness,
  • 0:53 - 0:56
    we can train a computer
  • 0:56 - 1:00
    to explore the exponentially larger space
  • 1:00 - 1:04
    of essentially all possible molecules
    that could be synthesized,
  • 1:04 - 1:10
    and thus instead of looking
    for a needle in a haystack,
  • 1:10 - 1:14
    we can use the giant magnet
    of computing power
  • 1:14 - 1:19
    to find many needles
    in multiple haystacks simultaneously.
  • 1:19 - 1:20
    We've already had some early success.
  • 1:20 - 1:25
    Recently, we used machine learning
  • 1:25 - 1:28
    to discover new antibiotics
    that can help us fight off
  • 1:28 - 1:33
    the bacterial infections that can occur
    alongside SARS-CoV-2 infections.
  • 1:33 - 1:36
    Two months ago, TED's Audacious Project
  • 1:36 - 1:39
    approved funding for us
    to massively scale up our work
  • 1:39 - 1:44
    with the goal of discovering
    seven new classes of antibiotics
  • 1:44 - 1:47
    against seven of the world's
    deadly bacterial pathogens
  • 1:48 - 1:51
    over the next seven years.
  • 1:51 - 1:52
    For context,
  • 1:52 - 1:55
    the number of new class of antibiotics
  • 1:55 - 1:58
    that have been discovered
    over the last three decades is zero.
  • 1:58 - 2:02
    While the quest for new antibiotics
    is for our medium-term future,
  • 2:02 - 2:06
    the novel coronavirus
    poses an immediate deadly threat,
  • 2:07 - 2:10
    and I'm excited to share that we think
    we can use the same technology
  • 2:10 - 2:14
    to search for therapeutics
    to fight this virus.
  • 2:14 - 2:16
    So how are we going to do it?
  • 2:16 - 2:18
    Well, we're creating
    a compound training library,
  • 2:18 - 2:22
    and with collaborators
    applying these molecules
  • 2:22 - 2:24
    to SARS-CoV-2-infected cells
  • 2:24 - 2:28
    to see which of them exhibit
    effective activity.
  • 2:28 - 2:32
    These data will be use to train
    a machine learning model
  • 2:32 - 2:36
    that will be applied to a [?]
    library of over a billion molecules
  • 2:36 - 2:41
    to search for potential
    novel antiviral compounds.
  • 2:41 - 2:43
    We will synthesize and test
    the top predictions
  • 2:43 - 2:46
    and advance the most promising
    candidates into the clinic.
  • 2:47 - 2:49
    Sound too good to be true?
  • 2:49 - 2:50
    Well, it shouldn't.
  • 2:50 - 2:53
    The Antibiotics AI Project is founded
    on our proof of concept research
  • 2:53 - 2:57
    that led to the discovery
    of a novel broad spectrum antibiotic
  • 2:57 - 2:58
    called Halocin.
  • 2:59 - 3:01
    Halocin has potent antibacterial activity
  • 3:01 - 3:06
    against almost all antibiotic-resistant
    bacterial pathogens,
  • 3:06 - 3:09
    including untreatable
    pan-resistant infections.
  • 3:10 - 3:12
    Importantly, in contrast
    to current antibiotics,
  • 3:12 - 3:16
    the frequency at which bacteria
    develop resistance against Halocin
  • 3:16 - 3:18
    is remarkably low.
  • 3:18 - 3:23
    We tested the ability of bacteria
    to evolve resistance against Halocin
  • 3:23 - 3:25
    as well as Cipro in the lab.
  • 3:25 - 3:27
    In the case of Cipro,
  • 3:27 - 3:30
    after just one day, we saw resistance.
  • 3:30 - 3:32
    In the case of Halocin,
  • 3:32 - 3:35
    after one day we didn't
    see any resistance.
  • 3:35 - 3:38
    Amazingly, after even 30 days,
  • 3:38 - 3:41
    we didn't see any
    resistance against Halocin.
  • 3:41 - 3:47
    In this pilot project, we first tested
    roughly 2,500 compounds against E. coli.
  • 3:47 - 3:50
    This training set included
    known antibiotics,
  • 3:50 - 3:52
    such as Cipro and penicillin,
  • 3:52 - 3:55
    as well as many drugs
    that are not antibiotics.
  • 3:55 - 3:58
    These data we used to train a model
  • 3:58 - 4:02
    to learn molecular features
    associated with antibacterial activity.
  • 4:02 - 4:06
    We then applied this model
    to a drug repurposing library
  • 4:06 - 4:08
    consisting of several thousand molecules,
  • 4:08 - 4:10
    and asked the model to identify molecules
  • 4:10 - 4:13
    that are predicted
    to have antibacterial properties
  • 4:13 - 4:16
    but don't look like existing antibiotics.
  • 4:16 - 4:21
    Interestingly, only one molecule
    in that library fit these criteria,
  • 4:22 - 4:24
    and that molecule
    turned out to be Halocin.
  • 4:25 - 4:28
    Given that Halocin does not look
    like any existing antibiotic,
  • 4:28 - 4:32
    it would have been impossible for a human,
    including an antibiotic expert,
  • 4:32 - 4:35
    to identify Halocin in this manner.
  • 4:35 - 4:38
    Imagine now what we could do
    with this technology
  • 4:38 - 4:40
    against SARS-CoV-2.
  • 4:40 - 4:43
    And that's not all.
  • 4:43 - 4:44
    We're also using the tools
    of synthetic biology,
  • 4:44 - 4:47
    tinkering with DNA
    and other cellular machinery,
  • 4:47 - 4:50
    to serve human purposes
    like combating COVID-19,
  • 4:50 - 4:54
    and at [??] we are working
    to develop a protective mask
  • 4:54 - 4:58
    that can also serve
    as a rapid diagnostic test.
  • 4:58 - 5:00
    So how does that work?
  • 5:00 - 5:03
    Well, we recently showed that you can take
  • 5:03 - 5:04
    the cellular machinery
    out of a living cell
  • 5:04 - 5:08
    and freeze-dry it along with
    RNA sensors onto paper
  • 5:08 - 5:13
    in order to create low-cost
    diagnostics for Ebola and Zika.
  • 5:14 - 5:18
    The sensors are activated when
    they're rehydrated by a patient sample
  • 5:18 - 5:22
    that could consist of blood
    or saliva, for example.
  • 5:22 - 5:25
    It turns out this technology
    is not limited to paper
  • 5:25 - 5:29
    and can be applied
    to other materials, including cloth.
  • 5:29 - 5:31
    For the COVID-19 pandemic,
    we're designing RNA sensors
  • 5:31 - 5:33
    to detect the virus
  • 5:33 - 5:38
    and freeze-drying these
    along with the needed cellular machinery
  • 5:38 - 5:41
    into the fabric of a face mask,
  • 5:41 - 5:43
    where the simple act of breathing,
  • 5:43 - 5:48
    along with the water vapor
    that comes with it, can activate the test.
  • 5:48 - 5:51
    Now, if the patient
    is infected with SARS-CoV-2,
  • 5:52 - 5:56
    the mask will produce a fluorescent signal
    that can be detected by a simple,
  • 5:56 - 5:59
    inexpensive handheld device.
  • 5:59 - 6:01
    In one or two hours, a patient
    could those be diagnosed
  • 6:01 - 6:06
    safely, remotely and accurately.
  • 6:07 - 6:10
    We're also using synthetic biology
  • 6:10 - 6:13
    to design a candidate
    vaccine for COVID-19.
  • 6:13 - 6:16
    We are repurposing the BCG vaccine,
  • 6:16 - 6:19
    which has been used against TB
    for almost a century.
  • 6:19 - 6:20
    It's a live attenuated vaccine,
  • 6:20 - 6:24
    and we're engineering it
    to express SARS-CoV-2 antigens,
  • 6:25 - 6:28
    which should trigger the production
    of protective antibodies
  • 6:28 - 6:30
    by the immune system.
  • 6:30 - 6:34
    Importantly, BCG is massively scalable
    and has a safety profile
  • 6:34 - 6:37
    that's among the best
    of any reported vaccine.
  • 6:38 - 6:43
    With the tools of synthetic biology
    and artificial intelligence,
  • 6:43 - 6:47
    we can win the fight
    against this novel coronavirus.
  • 6:47 - 6:50
    This work is in its very early stages,
    but the promise is real.
  • 6:50 - 6:55
    Science and technology
    can give us an important advantage
  • 6:55 - 6:58
    in the battle of human wits
    versus the genes of superbugs,
  • 6:58 - 7:00
    a battle we can win.
  • 7:00 - 7:02
    Thank you.
Title:
How we're using AI to discover new antibiotics
Speaker:
Jim Collins
Description:

more » « less
Video Language:
English
Team:
closed TED
Project:
TEDTalks
Duration:
07:15
  • English transcript correction:

    Halocin --> halicin

English subtitles

Revisions Compare revisions